1,721,084 research outputs found
LONGTERMS_supplementary_ – Supplemental material for Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results
No full textSupplemental material, LONGTERMS_supplementary_ for Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results by Jeffrey A. Cohen, Nadia Tenenbaum, Alit Bhatt, Ying Zhang and Ludwig Kappos in Therapeutic Advances in Neurological Disorders</p
sj-docx-1-msj-10.1177_13524585221089534 – Supplemental material for Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies
No full textSupplemental material, sj-docx-1-msj-10.1177_13524585221089534 for Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies by Till Sprenger, Ludwig Kappos, Maria Pia Sormani, Aaron E Miller, Elizabeth M Poole, Steven Cavalier and Jens Wuerfel in Multiple Sclerosis Journal</p
sj-docx-1-msj-10.1177_13524585221125382 – Supplemental material for Recurrent disability progression endpoints in multiple sclerosis clinical trials
No full textSupplemental material, sj-docx-1-msj-10.1177_13524585221125382 for Recurrent disability progression endpoints in multiple sclerosis clinical trials by Alexandra Bühler, Marcel Wolbers, Fabian Model, Qing Wang, Shibeshih Belachew, Marianna Manfrini, Johannes Lorscheider, Ludwig Kappos and Jan Beyersmann in Multiple Sclerosis Journal</p
MSJ768433_supplementary_material – Supplemental material for Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing–remitting multiple sclerosis
No full textSupplemental material, MSJ768433_supplementary_material for Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing–remitting multiple sclerosis by Johannes Lorscheider, Pascal Benkert, Carmen Lienert, Peter Hänni, Tobias Derfuss, Jens Kuhle, Ludwig Kappos and Özgür Yaldizli in Multiple Sclerosis Journal</p
MSJ855722_supplementary_materials – Supplemental material for Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide
No full textSupplemental material, MSJ855722_supplementary_materials for Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide by Till Sprenger, Ludwig Kappos, Ernst-Wilhelm Radue, Laura Gaetano, Nicole Mueller-Lenke, Jens Wuerfel, Elizabeth M Poole and Steven Cavalier in Multiple Sclerosis Journal</p
sj-docx-1-tan-10.1177_17562864241239101 – Supplemental material for Serum neurofilament light chain correlations in patients with a first clinical demyelinating event in the REFLEX study: a post hoc analysis
No full textSupplemental material, sj-docx-1-tan-10.1177_17562864241239101 for Serum neurofilament light chain correlations in patients with a first clinical demyelinating event in the REFLEX study: a post hoc analysis by Jens Kuhle, David Leppert, Giancarlo Comi, Nicola de Stefano, Ludwig Kappos, Mark S. Freedman, Andrea Seitzinger and Sanjeev Roy in Therapeutic Advances in Neurological Disorders</p
MSJ765666_supplementary_figure_1 – Supplemental material for Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis
No full textSupplemental material, MSJ765666_supplementary_figure_1 for Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis by Nelly Siller, Jens Kuhle, Muthuraman Muthuraman, Christian Barro, Timo Uphaus, Sergiu Groppa, Ludwig Kappos, Frauke Zipp and Stefan Bittner in Multiple Sclerosis Journal</p
sj-pdf-2-msj-10.1177_1352458518814117 – Supplemental material for Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions
No full textSupplemental material, sj-pdf-2-msj-10.1177_1352458518814117 for Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions by Colm Elliott, Jerry S Wolinsky, Stephen L Hauser, Ludwig Kappos, Frederik Barkhof, Corrado Bernasconi, Wei Wei, Shibeshih Belachew and Douglas L Arnold in Multiple Sclerosis Journal</p
sj-docx-1-msj-10.1177_13524585221144742 – Supplemental material for Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial
No full textSupplemental material, sj-docx-1-msj-10.1177_13524585221144742 for Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial by Jens Kuhle, Tanuja Chitnis, Brenda Banwell, Marc Tardieu, Douglas L Arnold, Andreea M Rawlings, Svend S Geertsen, Alex L Lublin, Stephane Saubadu, Philippe Truffinet and Ludwig Kappos in Multiple Sclerosis Journal</p
sj-docx-1-msj-10.1177_13524585231195346 – Supplemental material for Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension
No full textSupplemental material, sj-docx-1-msj-10.1177_13524585231195346 for Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension by Stephen L Hauser, Ronald Zielman, Ayan Das Gupta, Jing Xi, Dee Stoneman, Goeril Karlsson, Derrick Robertson, Jeffrey A Cohen and Ludwig Kappos in Multiple Sclerosis Journal</p
- …
